64513 Continuous response with nemolizumab up to 56 weeks during a long-term extension study in patients with moderate-to-severe atopic dermatitis and partial or delayed skin response at Week 16 – Post-hoc analyses from the pooled ARCADIA 1&2 trials and long-te
Recommended Citation
Silverberg JI, Stein Gold LF, Thaci D, Pink A, Papp K, Legat FJ, Yeon Cheong S, Ryzhkova A, Ulianov L, Piketty C. 64513 Continuous response with nemolizumab up to 56 weeks during a long-term extension study in patients with moderate-to-severe atopic dermatitis and partial or delayed skin response at Week 16 – Post-hoc analyses from the pooled ARCADIA 1&2 trials and long-te. J Am Acad Dermatol 2025; 93:AB157.
Document Type
Conference Proceeding
Publication Date
9-1-2025
Publication Title
J Am Acad Dermatol
Abstract
Introduction: Atopic dermatitis (AD) is a chronic, neuroimmune skin disease characterized by intense itch and eczematous lesions.[1,2] Nemolizumab, a first-in-class humanized monoclonal antibody, showed efficacy in two Phase 3 trials (ARCADIA 1&2 [NCT03985943, NCT03989349]). [3] However, AD is heterogeneous, and treatment responses can vary.[4] This post-hoc analysis investigated the extended effects of nemolizumab on patients with partial or delayed skin response at Week 16 of the pivotal trials. Methods: This analysis examined two subpopulations of participants who did not achieve skin response: Partial responders (n=290; participants with ≥50% but <75% improvement in Eczema Area and Severity Index [EASI] or Investigator’s Global Assessment [IGA] 2/3, with ≥1-point improvement), and non-responders (n=207; participants who did not achieve EASI-50 and had IGA 3/4, with no improvement). Participants received nemolizumab 30 mg subcutaneously, with optional topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) every 4 weeks, as part of a long-term extension study (≤56 weeks). Results: By Week 56, substantial improvements in skin inflammation and itch were observed in both groups. Notably, 43% of partial responders and 36% of non-responders achieved IGA 0/1, while 71% and 66% achieved EASI-75, respectively. Significant improvements in pruritus were also observed, with 83% of partial responders and 80% of non-responders achieving a 4-point improvement in the Visual Analog Scale. Conclusion: While some participants with moderate-to-severe AD receiving nemolizumab may experience a delayed skin response, continued nemolizumab treatment with optional TCS/TCI may still lead to a meaningful clinical outcome in a longer term.
Volume
93
First Page
AB157
